Jaume Capdevila, MD, PhD, discusses phase 1 data showing promising efficacy and manageable safety for obrixtamig in patients with high DLL3-expressing extrapulmonary neuroendocrine carcinomas, along with ongoing trials evaluating its use in both monotherapy and combination settings.
Read More
Cholesterol-Lowering Drugs May Significantly Increase Risk of Diabetic Microvascular Complications
June 24th 2025HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, whereas NPC1L1 inhibitors were found to reduce the risk.
Read More
Psilocybin, Ketamine, and MDMA in Cancer Care: Next Steps in Psychedelic Research
June 24th 2025Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.
Watch
IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C
June 23rd 2025Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced the need for adjunctive immunotherapy following treatment.
Read More
ADA 2025: Ready-to-Use Glucagon Empowers Diabetes Patient Safety
Ready-to-use glucagon simplifies hypoglycemia rescue by providing easy-to-use options for patients and caregivers.
Watch
Psychedelic Group Therapy Expands From Cancer Care to Treat PTSD in Active Duty Military
June 23rd 2025Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military posttraumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.
Watch